Hybio Pharmaceutical Strategic Asset Allocation Index
Hybio Pharmaceutical strategic asset allocation index. Hybio Pharmaceutical (300199) has a Strategic Asset Allocation Index of 144.9% as of June 2023. Strategic assets (PP&E of CN¥1.86 Billion plus long-term investments of CN¥-) total CN¥1.86 Billion, measured against net assets of CN¥1.29 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Hybio Pharmaceutical (300199) tangible equity ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Hybio Pharmaceutical (2008–2022)
Strategic asset allocation index of Hybio Pharmaceutical from 2008 to 2022. This chart shows how Hybio Pharmaceutical's Strategic Asset Allocation Index has evolved across 15 annual periods from 2008 to 2022. As of June 2023, the index stands at 144.9%, representing strategic assets of CN¥1.86 Billion against net assets of CN¥1.29 Billion CNY.
Hybio Pharmaceutical Strategic Asset Allocation Index by Year (2008–2022)
Hybio Pharmaceutical strategic asset allocation index by year from 2008 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Hybio Pharmaceutical from 2008 to 2022, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300199 market cap.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 149.7% | CN¥1.94 Billion | CN¥1.94 Billion | CN¥- | CN¥1.30 Billion | ▲ +28.8 pp |
| 2021 | 120.9% | CN¥1.99 Billion | CN¥1.99 Billion | CN¥- | CN¥1.65 Billion | ▲ +2.9 pp |
| 2020 | 118.0% | CN¥1.98 Billion | CN¥1.98 Billion | CN¥- | CN¥1.68 Billion | ▲ +37.8 pp |
| 2019 | 80.2% | CN¥1.79 Billion | CN¥1.79 Billion | CN¥- | CN¥2.23 Billion | ▲ +34.6 pp |
| 2018 | 45.6% | CN¥1.55 Billion | CN¥1.33 Billion | CN¥217.71 Million | CN¥3.39 Billion | ▲ +14.4 pp |
| 2017 | 31.1% | CN¥1.21 Billion | CN¥1.06 Billion | CN¥149.95 Million | CN¥3.88 Billion | ▲ +0.1 pp |
| 2016 | 31.1% | CN¥1.12 Billion | CN¥965.08 Million | CN¥155.54 Million | CN¥3.60 Billion | ▼ -8.8 pp |
| 2015 | 39.9% | CN¥1.05 Billion | CN¥917.62 Million | CN¥134.29 Million | CN¥2.64 Billion | ▼ -1.6 pp |
| 2014 | 41.5% | CN¥537.70 Million | CN¥537.70 Million | CN¥- | CN¥1.30 Billion | ▼ -4.2 pp |
| 2013 | 45.7% | CN¥514.03 Million | CN¥514.03 Million | CN¥- | CN¥1.12 Billion | ▲ +16.6 pp |
| 2012 | 29.1% | CN¥295.85 Million | CN¥295.85 Million | CN¥- | CN¥1.02 Billion | ▲ +19.8 pp |
| 2011 | 9.3% | CN¥90.71 Million | CN¥90.71 Million | CN¥- | CN¥976.09 Million | ▼ -27.8 pp |
| 2010 | 37.1% | CN¥66.91 Million | CN¥66.91 Million | CN¥- | CN¥180.59 Million | ▼ -2.3 pp |
| 2009 | 39.3% | CN¥50.25 Million | CN¥50.25 Million | CN¥- | CN¥127.74 Million | ▼ -12.0 pp |
| 2008 | 51.3% | CN¥50.95 Million | CN¥50.95 Million | CN¥- | CN¥99.23 Million | — |